Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Enanta Pharmaceutica (ENTA)

Enanta Pharmaceutica (ENTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,197,452
  • Shares Outstanding, K 19,682
  • Annual Sales, $ 206,630 K
  • Annual Income, $ 71,960 K
  • 60-Month Beta 0.93
  • Price/Sales 5.68
  • Price/Cash Flow 15.63
  • Price/Book 2.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.56
  • Number of Estimates 4
  • High Estimate 1.10
  • Low Estimate 0.34
  • Prior Year 1.30
  • Growth Rate Est. (year over year) -56.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.15 +4.48%
on 10/09/19
73.39 -18.65%
on 09/24/19
-10.99 (-15.54%)
since 09/18/19
3-Month
57.15 +4.48%
on 10/09/19
84.73 -29.53%
on 07/19/19
-23.72 (-28.43%)
since 07/18/19
52-Week
57.15 +4.48%
on 10/09/19
106.80 -44.09%
on 03/04/19
-19.13 (-24.26%)
since 10/18/18

Most Recent Stories

More News
New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced...

ENTA : 59.71 (-1.86%)
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of MAVYRET® (glecaprevir/pibrentasvir) to...

ABBV : 76.46 (+1.76%)
ENTA : 59.71 (-1.86%)
SmarTrend Watching for Potential Rebound in Shares of Enanta Pharmaceu After 16.05% Loss

Enanta Pharmaceu (NASDAQ:ENTA) traded in a range yesterday that spanned from a low of $58.03 to a high of $72.72. Yesterday, the shares fell 16.0%, which took the trading range below the 3-day low of...

ENTA : 59.71 (-1.86%)
Enanta's Stock Down Despite NASH Drug Meeting Goal in Study

Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.

NVO : 52.52 (-0.30%)
GILD : 64.91 (-0.49%)
ICPT : 65.07 (+1.02%)
ENTA : 59.71 (-1.86%)
Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced...

ENTA : 59.71 (-1.86%)
Enanta Pharmaceu Down 15.1% Since SmarTrend Downtrend Call (ENTA)

SmarTrend identified a Downtrend for Enanta Pharmaceu (NASDAQ:ENTA) on June 24th, 2019 at $84.49. In approximately 3 months, Enanta Pharmaceu has returned 15.06% as of today's recent price of $71.77.

ENTA : 59.71 (-1.86%)
17.3% Return Seen to Date on SmarTrend Enanta Pharmaceu Call (ENTA)

SmarTrend identified a Downtrend for Enanta Pharmaceu (NASDAQ:ENTA) on June 24th, 2019 at $84.49. In approximately 3 months, Enanta Pharmaceu has returned 17.28% as of today's recent price of $69.89.

ENTA : 59.71 (-1.86%)
New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek(TM) 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced...

ENTA : 59.71 (-1.86%)
Oversold Conditions For Enanta Pharmaceuticals (ENTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

ENTA : 59.71 (-1.86%)
Enanta Pharmaceu Has Returned 20.8% Since SmarTrend Recommendation (ENTA)

SmarTrend identified a Downtrend for Enanta Pharmaceu (NASDAQ:ENTA) on June 24th, 2019 at $84.49. In approximately 3 months, Enanta Pharmaceu has returned 20.81% as of today's recent price of $66.91.

ENTA : 59.71 (-1.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ENTA with:

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

2nd Resistance Point 61.78
1st Resistance Point 60.74
Last Price 59.71
1st Support Level 59.05
2nd Support Level 58.39

See More

52-Week High 106.80
Fibonacci 61.8% 87.83
Fibonacci 50% 81.98
Fibonacci 38.2% 76.12
Last Price 59.71
52-Week Low 57.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar